Effect of background therapy with Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents on COVID-19 outcomes
Lucio Miele, San Chu, William Hillegass, Claudine Jurkovitz, William Beasley, David Chen, A Jerrod Anzalone, Daniel Fort, John Kirwan, Brian Melancon, Sally Hodder, Ronald Horswell
doi:10.1101/2024.12.07.24318645
Background: Inflammation plays a complex, incompletely understood role in the pathogenesis of acute COVID-19 and Post-Acute Sequelae of SARS-CoV-2 infection (PASC or "Long COVID"). Systemic acute inflammation resulting in cytokine storm, hypercoagulability and endothelial damage is thought to be a central mechanism for severe morbidity and mortality in acute COVID-19. Anti-inflammatory medications taken routinely for chronic conditions prior to contracting COVID-19 ("background medications") may modulate acute COVID-19 outcomes. Methods: Using data from the National COVID Cohort Collaborative (N3C) enclave, we estimated effects of six classes of background medications on acute COVID outcomes. Medication classes included aspirin, celecoxib, other NSAIDS, steroids, immune suppressants, and antidepressants. Acute COVID outcomes included probability of hospital admission, inpatient mortality, and mortality among diagnosed COVID patients. Each medication class was compared to benzodiazepines (excluding midazolam) which served as a comparator/control. Only adult COVID patients with pre-existing osteoarthritis and without any diagnosed autoimmune disease were included in the analyses. Random effects logistic regression models were used to adjust for covariates and data contributing organization. Medication effects also were estimated for COVID-negative cases. Results: Non-aspirin NSAIDS were associated with lower mortality among diagnosed COVID-19 patients: adjusted Odds Ratio (aOR)=0.32 (p=.032) for celecoxib; aOR=0.51 (p<.001) for NSAIDS other than aspirin and celecoxib. For inpatient mortality: aOR=0.34 (p=.060) for celecoxib and aOR=0.74 (p=.200) for other non-aspirin NSAIDS. Similar effects were observed for COVID-negative cases, including for inpatient mortality: aOR=0.21 (p<.001) for celecoxib and .
References
Abdelhaleem, Kassab, El-Nassan, Khalil, Recent advances in the development of celecoxib analogs as anticancer agents: A review, Arch Pharm (Weinheim),
doi:10.1002/ardp.202200326Baghaki, Yalcin, Baghaki, Aydin, Daghan et al., COX2 inhibition in the treatment of COVID-19: Review of literature to propose repositioning of celecoxib for randomized controlled studies, Int J Infect Dis,
doi:10.1016/j.ijid.2020.09.1466Bahmani, Chegini, Ghanbari, Sheykhsaran, Aghbash et al., Severe acute respiratory syndrome coronavirus 2 infection: Role of interleukin-6 and the inflammatory cascade, World J Virol,
doi:10.5501/wjv.v11.i3.113Boroujeni, Sekrecka, Antonczyk, Hassani, Sekrecki et al., Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy, Front Immunol,
doi:10.3389/fimmu.2022.888897Borton, Bhangoo, Quah, Stephen, Howard, Aspirin monotherapy is a suitable standard thromboprophylactic agent following total hip arthroplasty, Hip Int,
doi:10.1177/1120700021990544Christopher, Chute, Hopkins University ; Anzalone, Manna, Saha et al., Oxidative Stress and Hyper-Inflammation as Major Drivers of Severe COVID-19 and Long COVID: Implications for the Benefit of High-Dose Intravenous Vitamin C, Front Pharmacol,
doi:10.3389/fphar.2022.899198Danziger-Isakov, Blumberg, Manuel, Sester, Impact of COVID-19 in solid organ transplant recipients, Am J Transplant,
doi:10.1111/ajt.16449El-Malah, Gineinah, Deb, Khayyat, Bansal et al., Selective COX-2 Inhibitors: Road from Success to Controversy and the Quest for Repurposing, Pharmaceuticals,
doi:10.3390/ph15070827Eyitemi, Thomas, Ramos, Feng, Ezekwesili, SARS-CoV-2: Review of Conditions Associated With Severe Disease and Mortality, Int J Prev Med,
doi:10.4103/ijpvm.IJPVM_640_20Ghaznavi, Mohammadghasemipour, Shirvaliloo, Momeni, Metanat et al., Short-term celecoxib (celebrex) adjuvant therapy: a clinical trial study on COVID-19 patients, Inflammopharmacology,
doi:10.1007/s10787-022-01029-4Gimeno, Mestres-Truyol, Ojeda-Montes, Macip, Saldivar-Espinoza et al., Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition, Int J Mol Sci,
doi:10.3390/ijms21113793Haendel, Chute, Bennett, The National COVID Cohort Collaborative (N3C): Rationale, design, infrastructure, and deployment, J Am Med Inform Assoc,
doi:10.1093/jamia/ocaa196Hsieh, Wang, Chen, Zhao, Savitz et al., Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidence, Sci Rep,
doi:10.1038/s41598-021-02353-5Ipema, Brand, Deb, Dev, Unl, Antiplatelet and anticoagulation therapy after revascularization for lower extremity artery disease: a national survey and literature overview, J Cardiovasc Surg,
doi:10.23736/S0021-9509.20.11402-2Jin, Qian, Lin, Liu, Cyclooxygenase-2-Prostaglandin E2 pathway: A key player in tumor-associated immune cells, Front Oncol,
doi:10.3389/fonc.2023.1099811Micallef, Soeiro, Ap, French Society of Pharmacology T. Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection, Therapie,
doi:10.1016/j.therap.2020.05.003Montazersaheb, Khatibi, Hejazi, Tarhriz, Farjami et al., COVID-19 infection: an overview on cytokine storm and related interventions, Virol J,
doi:10.1186/s12985-022-01814-1Newell, Waickman, Inflammation, immunity, and antigen persistence in postacute sequelae of SARS-CoV-2 infection, Curr Opin Immunol,
doi:10.1016/j.coi.2022.102228Newman, Muscat, Potential Role of Non-Steroidal Anti-Inflammatory Drugs in Colorectal Cancer Chemoprevention for Inflammatory Bowel Disease: An Umbrella Review, Cancers,
doi:10.3390/cancers15041102Nso, Nassar, Zirkiyeva, Mbome, Ngonge et al., Factors Impacting Stent Thrombosis in Patients With Percutaneous Coronary Intervention and Coronary Stenting: A Systematic Review and Meta-Analysis, Cureus,
doi:10.7759/cureus.23973Obeid, Libby, Husni, Wang, Wisniewski et al., Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial, Eur Heart J Cardiovasc Pharmacother,
doi:10.1093/ehjcvp/pvac015Quan-Charlson Paper Here: Quan, Li, Couris, Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries, Am J Epidemiol,
doi:10.1093/aje/kwq433Rashid, Khan, Elsori, Rehman, Tanzeelah et al., Non-steroidal antiinflammatory drugs and biomarkers: A new paradigm in colorectal cancer, Front Med,
doi:10.3389/fmed.2023.1130710Reese, Coleman, Chan, Blau, Callahan et al., NSAID use and clinical outcomes in COVID-19 patients: a 38-center retrospective cohort study, Virol J,
doi:10.1186/s12985-022-01813-2Vasudeva, Challa, Rifai, Polana, Duran et al., Prevalence of cardiovascular diseases in COVID-19 related mortality in the United States, Prog Cardiovasc Dis,
doi:10.1016/j.pcad.2022.09.002Whoreafc, Sterne, Murthy, Diaz, Slutsky et al., Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis, JAMA,
doi:10.1001/jama.2020.17023Ye, Li, Li, Song, Sun et al., The Efficacy and Safety of Celecoxib in Addition to Standard Cancer Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Curr Oncol,
doi:10.3390/curroncol29090482Zhang, Qin, Fei, Shen, Zhou et al., Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update, Clin Immunol,
doi:10.1016/j.clim.2022.109022DOI record:
{
"DOI": "10.1101/2024.12.07.24318645",
"URL": "http://dx.doi.org/10.1101/2024.12.07.24318645",
"abstract": "<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Inflammation plays a complex, incompletely understood role in the pathogenesis of acute COVID-19 and Post-Acute Sequelae of SARS-CoV-2 infection (PASC or “Long COVID”). Systemic acute inflammation resulting in cytokine storm, hypercoagulability and endothelial damage is thought to be a central mechanism for severe morbidity and mortality in acute COVID-19. Anti-inflammatory medications taken routinely for chronic conditions prior to contracting COVID-19 (“background medications”) may modulate acute COVID-19 outcomes.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Using data from the National COVID Cohort Collaborative (N3C) enclave, we estimated effects of six classes of background medications on acute COVID outcomes. Medication classes included aspirin, celecoxib, other NSAIDS, steroids, immune suppressants, and antidepressants. Acute COVID outcomes included probability of hospital admission, inpatient mortality, and mortality among diagnosed COVID patients. Each medication class was compared to benzodiazepines (excluding midazolam) which served as a comparator/control. Only adult COVID patients with pre-existing osteoarthritis and without any diagnosed autoimmune disease were included in the analyses. Random effects logistic regression models were used to adjust for covariates and data contributing organization. Medication effects also were estimated for COVID-negative cases.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Non-aspirin NSAIDS were associated with lower mortality among diagnosed COVID-19 patients: adjusted Odds Ratio (aOR)=0.32 (p=.032) for celecoxib; aOR=0.51 (p<.001) for NSAIDS other than aspirin and celecoxib. For inpatient mortality: aOR=0.34 (p=.060) for celecoxib and aOR=0.74 (p=.200) for other non-aspirin NSAIDS. Similar effects were observed for COVID-negative cases, including for inpatient mortality: aOR=0.21 (p<.001) for celecoxib and aOR=0.34 (p<.001) for other non-aspirin NSAIDS. Secondary analyses examined alternative explanations for results.</jats:p></jats:sec><jats:sec><jats:title>Discussion</jats:title><jats:p>Protective effects were observed for non-aspirin NSAIDS, especially celecoxib. However, those estimated effects implicitly assume the medication classes did not differ on the probability a true COVID-19 case was diagnosed. The similarity of COVID-positive and COVID-negative results suggest possible missing covariates. However, such similarity plausibly could stem from a medication having both “direct” and “indirect” effects on COVID outcomes. Adjudicating among the alternative interpretations would require data beyond those available. However, the effects observed for non-aspirin NSAIDS, while possibly biased, rationalize further investigation using study designs constructed to overcome the limitations of existing datasets.</jats:p></jats:sec>",
"accepted": {
"date-parts": [
[
2024,
12,
8
]
]
},
"author": [
{
"ORCID": "https://orcid.org/0000-0002-5853-7287",
"affiliation": [],
"authenticated-orcid": false,
"family": "Miele",
"given": "Lucio",
"sequence": "first"
},
{
"ORCID": "https://orcid.org/0000-0003-3058-824X",
"affiliation": [],
"authenticated-orcid": false,
"family": "Chu",
"given": "San",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Hillegass",
"given": "William",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Jurkovitz",
"given": "Claudine",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Beasley",
"given": "William",
"sequence": "additional"
},
{
"ORCID": "https://orcid.org/0000-0003-4140-459X",
"affiliation": [],
"authenticated-orcid": false,
"family": "Chen",
"given": "David",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Anzalone",
"given": "A Jerrod",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Fort",
"given": "Daniel",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Kirwan",
"given": "John",
"sequence": "additional"
},
{
"ORCID": "https://orcid.org/0000-0003-1999-4351",
"affiliation": [],
"authenticated-orcid": false,
"family": "Melancon",
"given": "Brian",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Hodder",
"given": "Sally",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Horswell",
"given": "Ronald",
"sequence": "additional"
}
],
"container-title": [],
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2024,
12,
9
]
],
"date-time": "2024-12-09T05:05:45Z",
"timestamp": 1733720745000
},
"deposited": {
"date-parts": [
[
2024,
12,
10
]
],
"date-time": "2024-12-10T12:10:20Z",
"timestamp": 1733832620000
},
"group-title": "Public and Global Health",
"indexed": {
"date-parts": [
[
2024,
12,
11
]
],
"date-time": "2024-12-11T16:11:07Z",
"timestamp": 1733933467579,
"version": "3.30.2"
},
"institution": [
{
"name": "medRxiv"
}
],
"is-referenced-by-count": 0,
"issued": {
"date-parts": [
[
2024,
12,
8
]
]
},
"license": [
{
"URL": "http://creativecommons.org/licenses/by/4.0/",
"content-version": "vor",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2024,
12,
8
]
],
"date-time": "2024-12-08T00:00:00Z",
"timestamp": 1733616000000
}
}
],
"link": [
{
"URL": "https://syndication.highwire.org/content/doi/10.1101/2024.12.07.24318645",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "246",
"original-title": [],
"posted": {
"date-parts": [
[
2024,
12,
8
]
]
},
"prefix": "10.1101",
"published": {
"date-parts": [
[
2024,
12,
8
]
]
},
"publisher": "Cold Spring Harbor Laboratory",
"reference": [
{
"DOI": "10.3389/fphar.2022.899198",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.1"
},
{
"DOI": "10.1186/s12985-022-01814-1",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.2"
},
{
"DOI": "10.3389/fimmu.2022.888897",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.3"
},
{
"DOI": "10.5501/wjv.v11.i3.113",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.4"
},
{
"DOI": "10.1016/j.coi.2022.102228",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.5"
},
{
"DOI": "10.1001/jama.2020.17023",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.6"
},
{
"DOI": "10.1016/j.clim.2022.109022",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.7"
},
{
"DOI": "10.1016/j.therap.2020.05.003",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.8"
},
{
"DOI": "10.1016/j.heliyon.2022.e09544",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.9"
},
{
"DOI": "10.1093/jamia/ocaa196",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.10"
},
{
"DOI": "10.1186/s12985-022-01813-2",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.11"
},
{
"DOI": "10.1093/aje/kwq433",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.12"
},
{
"DOI": "10.1111/ajt.16449",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.13"
},
{
"DOI": "10.7759/cureus.23973",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.14"
},
{
"DOI": "10.1177/1120700021990544",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.15"
},
{
"DOI": "10.23736/S0021-9509.20.11402-2",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.16"
},
{
"DOI": "10.1016/j.cpcardiol.2020.100553",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.17"
},
{
"DOI": "10.1016/j.pcad.2022.09.002",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.18"
},
{
"DOI": "10.1016/j.ijid.2020.09.1466",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.19"
},
{
"DOI": "10.1007/s10787-022-01029-4",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.20"
},
{
"DOI": "10.1038/s41598-023-40033-8",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.21"
},
{
"DOI": "10.1038/s41598-021-02353-5",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.22"
},
{
"DOI": "10.3390/ijms21113793",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.23"
},
{
"DOI": "10.4049/jimmunol.1101029",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.24"
},
{
"DOI": "10.1093/ehjcvp/pvac015",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.25"
},
{
"DOI": "10.1186/s12935-015-0260-7",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.26"
},
{
"DOI": "10.3389/fonc.2023.1099811",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.27"
},
{
"DOI": "10.3390/curroncol29090482",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.28"
},
{
"DOI": "10.1124/jpet.122.001631",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.29"
},
{
"DOI": "10.3389/fmed.2023.1130710",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.30"
},
{
"DOI": "10.3390/cancers15041102",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.31"
},
{
"DOI": "10.2174/2772270816666220829090716",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.32"
},
{
"DOI": "10.1002/ardp.202200326",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.33"
},
{
"DOI": "10.3390/ph15070827",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.34"
},
{
"DOI": "10.4103/ijpvm.IJPVM_640_20",
"doi-asserted-by": "publisher",
"key": "2024121004101106000_2024.12.07.24318645v1.35"
}
],
"reference-count": 35,
"references-count": 35,
"relation": {},
"resource": {
"primary": {
"URL": "http://medrxiv.org/lookup/doi/10.1101/2024.12.07.24318645"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"subtype": "preprint",
"title": "Effect of background therapy with Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents on COVID-19 outcomes",
"type": "posted-content"
}
